Nothing Special   »   [go: up one dir, main page]

CO2022002781A2 - Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos - Google Patents

Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos

Info

Publication number
CO2022002781A2
CO2022002781A2 CONC2022/0002781A CO2022002781A CO2022002781A2 CO 2022002781 A2 CO2022002781 A2 CO 2022002781A2 CO 2022002781 A CO2022002781 A CO 2022002781A CO 2022002781 A2 CO2022002781 A2 CO 2022002781A2
Authority
CO
Colombia
Prior art keywords
receptor agonists
compounds
somatostatin type
peptide somatostatin
peptide
Prior art date
Application number
CONC2022/0002781A
Other languages
English (en)
Inventor
Jian Zhao
Yunfei Zhu
Shimiao Wang
Mi Chen
Joseph Pontillo
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of CO2022002781A2 publication Critical patent/CO2022002781A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se describen compuestos que son moduladores de somatostatina, métodos para preparar dichos compuestos, composiciones farmacéuticas y medicamentos que comprenden estos compuestos, y métodos para la utilización de dichos compuestos en el tratamiento de afecciones, enfermedades, o trastornos que pueden beneficiarse de la modulación de la actividad de la somatostatina.
CONC2022/0002781A 2019-08-14 2022-03-10 Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos CO2022002781A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962886764P 2019-08-14 2019-08-14
PCT/US2020/045610 WO2021030262A1 (en) 2019-08-14 2020-08-10 Nonpeptide somatostatin type 5 receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
CO2022002781A2 true CO2022002781A2 (es) 2022-06-21

Family

ID=74568328

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0002781A CO2022002781A2 (es) 2019-08-14 2022-03-10 Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos

Country Status (18)

Country Link
US (2) US11479540B2 (es)
EP (1) EP4013748A4 (es)
JP (1) JP7611893B2 (es)
KR (1) KR20220047318A (es)
CN (1) CN114585614B (es)
AR (1) AR119753A1 (es)
AU (1) AU2020327950A1 (es)
BR (1) BR112022002683A2 (es)
CA (1) CA3149840A1 (es)
CL (1) CL2022000354A1 (es)
CO (1) CO2022002781A2 (es)
IL (1) IL290479A (es)
MX (1) MX2022001874A (es)
PE (1) PE20221402A1 (es)
PH (1) PH12022550359A1 (es)
TW (1) TWI841768B (es)
WO (1) WO2021030262A1 (es)
ZA (1) ZA202201829B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51840A (fr) 2018-02-12 2021-05-19 Crinetics Pharmaceuticals Inc Modulateurs de somatostatine et leurs utilisations
AR116424A1 (es) 2018-09-18 2021-05-05 Crinetics Pharmaceuticals Inc Moduladores de la somatostatina y usos de los mismos
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
CA3207382A1 (en) * 2021-02-17 2022-08-25 Christine FERRARA-COOK Somatostatin receptor type 5 agonist for the treatment of hyperinsulinism
EP4294797A1 (en) 2021-02-17 2023-12-27 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024089668A1 (en) * 2022-10-28 2024-05-02 Basecamp Bio Inc. Somatostatin receptor 2 agonists and uses thereof
TW202440164A (zh) 2022-12-13 2024-10-16 美商克林提克斯醫藥股份有限公司 生長抑素亞型-2受體（sst2r）靶向治療劑及其用途
WO2025019256A1 (en) * 2023-07-14 2025-01-23 Crinetics Pharmaceuticals, Inc. Somatostatin subtype receptor 3 (sstr3) agonists and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127343A (en) 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
AU2007309708A1 (en) 2006-03-13 2008-05-02 Merck Sharp & Dohme Corp. Somatostatin agonists
BRPI0715967A2 (pt) * 2006-08-15 2013-08-06 Hoffmann La Roche compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodos para o tratamento e/ou prevenÇço de enfermidades que estço associadas com a modulaÇço de receptores de sst do subtipo 5, e uso destes compostos
EP2211619A1 (en) 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
JP2011526294A (ja) * 2008-06-25 2011-10-06 エンビボ ファーマシューティカルズ インコーポレイテッド ホスホジエステラーゼ１０阻害剤としての二置換フェニル化合物
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
GB201008290D0 (en) 2010-05-18 2010-06-30 Syngenta Ltd Chemical compounds
WO2011146324A1 (en) 2010-05-18 2011-11-24 Merck Sharp & Dohme Corp. Spiro isoxazoline compounds as sstr5 antagonists
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
US9643951B2 (en) 2013-09-30 2017-05-09 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
ES2675504T3 (es) 2013-10-02 2018-07-11 Kuraray Co., Ltd. Composición de resina, lámina de múltiples capas, material de envasado y recipiente
US9974778B2 (en) 2014-06-11 2018-05-22 Bristol-Myers Squibb Company Substituted pyridinones as MGAT2 inhibitors
KR102324042B1 (ko) 2016-07-14 2021-11-09 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 및 그의 용도
SG11201907240XA (en) 2017-02-08 2019-09-27 Ono Pharmaceutical Co Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
IL269241B (en) 2017-03-16 2022-09-01 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
EP3658560A4 (en) * 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
MA51840A (fr) 2018-02-12 2021-05-19 Crinetics Pharmaceuticals Inc Modulateurs de somatostatine et leurs utilisations
AR116424A1 (es) 2018-09-18 2021-05-05 Crinetics Pharmaceuticals Inc Moduladores de la somatostatina y usos de los mismos
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途

Also Published As

Publication number Publication date
PE20221402A1 (es) 2022-09-15
KR20220047318A (ko) 2022-04-15
CN114585614B (zh) 2024-12-03
CN114585614A (zh) 2022-06-03
TWI841768B (zh) 2024-05-11
EP4013748A4 (en) 2023-08-09
PH12022550359A1 (en) 2023-06-14
IL290479A (en) 2022-04-01
AR119753A1 (es) 2022-01-12
CA3149840A1 (en) 2021-02-18
TW202115008A (zh) 2021-04-16
AU2020327950A1 (en) 2022-03-17
CL2022000354A1 (es) 2022-10-21
BR112022002683A2 (pt) 2022-07-05
MX2022001874A (es) 2022-03-11
US20210047287A1 (en) 2021-02-18
US11479540B2 (en) 2022-10-25
JP2022544055A (ja) 2022-10-17
WO2021030262A1 (en) 2021-02-18
ZA202201829B (en) 2023-07-26
US20220144802A1 (en) 2022-05-12
EP4013748A1 (en) 2022-06-22
JP7611893B2 (ja) 2025-01-10

Similar Documents

Publication Publication Date Title
CO2022002781A2 (es) Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CO2018009071A2 (es) Derivados haloalilamina indol y azaindol como inhibidores de lisil-oxidasas y sus usos
MX2020001103A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2020004519A (es) Moduladores de la vía de estrés integrada.
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
UY37606A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
NZ757081A (en) Somatostatin modulators and uses thereof
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
MX2022007439A (es) Antagonistas de piperidina del receptor de melanocortina subtipo 2 (mc2r) sustituidos con gem y usos de los mismos.
DOP2021000071A (es) Compuestos heteroaromáticos como inhibidores de vanina
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
EA202091559A1 (ru) Способ получения модуляторов соматостатина
MX2021008941A (es) Moduladores gpr35.
DOP2021000021A (es) Compuestos heteroaromáticos como inhibidores de vanina
CL2019002583A1 (es) Inhibidores duales de magl y faah.
BR112022000855A2 (pt) Moduladores de nlrp3
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
DOP2018000127A (es) Derivados novedosos de diamino piridina
MX2021008748A (es) Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias.